ClinicalTrials.gg
RecruitingNCT06366490Updated Nov 20, 2026

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

A Phase 1 interventional study of Innocell in Ovarian Cancer (OvCa), sponsored by PhotonPharma, Inc.. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by PhotonPharma, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 20, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 275 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
1,276th of 1,499
12 · median 47
Started
2026
with 65 others
Phase 1
548 of 1,780
73 open now
Primary completion
2028-11
later than 345 of 450 live
Registered
1,598th of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 1,276th largest by planned enrollment of the 1,499 interventional ones that give a count, is one of 66 that started in 2026, is one of 548 in phase 1, reaches primary completion later than 345 of the 450 other live ones, and was the 1,598th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

275 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1 study to evaluate the safety and immunogenicity of Innocell, an autologous cellular immunotherapy made from patient-derived tumor cells, in female patients with recurrent epithelial ovarian cancer.

Innocell autologous cellular immunotherapy consists of autologous tumor cells which have been inactivated using a proprietary light technology that inhibits cell replication while allowing for the cell to maintain antigen expression. These replication incompetent cells are then administered concurrently with an immunoadjuvant to stimulate a person's innate or adaptive immune response to vaccine antigens. This novel inactivation mechanism creates improved antigen presentation, specifically with presentation of the broad array of neoantigens unique to each patient's tumor.

Read the detailed description

This is a Phase 1, open-label, single-center, dose-finding study using a 3+3 design to evaluate the safety and tolerability of two dose cohorts (e.g., Dose Cohort -1; Dose Cohort 1) of Innocell autologous cellular immunotherapy (i.e., Innocell vaccine) in patients with recurrent epithelial ovarian cancer.

The study is a 2-part design. For each participant, Part 1 will involve tissue procurement and confirmation of the ability to manufacture the Innocell vaccine, followed by Part 2 which is the treatment phase, involving Innocell administration to patients.

Patients will have a safety follow-up 30 days and an end of study follow-up 60 days after the last dose of Innocell. Long-term follow-up to evaluate disease/survival status will continue every 3 months for 1 year following the end of study follow-up.

03

Conditions studied

  • Ovarian Cancer (OvCa)

Browse trials for

Keywords

  • Autologous vaccine
  • Autologous Cellular Immunotherapy
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years and female;
  2. Has or cytologically confirmed diagnosis of recurrent epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy and for whom single-agent therapy is appropriate as the next ;
  3. Been treated with available standard-of-care therapy likely to convey clinical benefit (i.e., PARP inhibitors for women with germline BRCA mutation and in homologous recombination repair deficiency based on prior molecular testing or bevacizumab as appropriate);
  4. Documented relapse or progression on or after the most recent line of therapy;
  5. Patients must have at least 2 sites of measurable or detectable disease. The team will target to collect 1.0 gram of tumor tissue that can be removed and be available for manufacturing;
  6. Eastern Collaborative Oncology Group () performance status (PS) 0-2;
  7. Recovery from toxicities to Grade 2 or less (except alopecia, peripheral neuropathy, and ototoxicity);
  8. Adequate hematological, hepatic, and renal function obtained ≤ 28 days prior to planned initiation of vaccine series
  9. Negative pregnancy test for women of and agree to practice a medically acceptable regimen throughout the participation in the clinical trial; and,
  10. Provide written for study participation.

Exclusion criteria

Exclusion Criteria:

  1. Patient known to be positive for or patient with active , , HTLV-1/2;
  2. Diagnosis of immunodeficiency, either primary or acquired;
  3. Active disease that required systemic disease modifying or treatment within the last 12 months. Replacement therapy (e.g., thyroxine or physiologic replacement therapy for adrenal or pituitary insufficiency, etc.) is permitted;

    Note: The following conditions are permitted (i.e., not exclusionary) if the condition does not require immunosuppressive treatment:

    • Type 1 diabetes (if stable, well controlled, and not brittle); Vitiligo; Hypo- or hyperthyroid disease; or Autoimmune alopecia.
  4. Treatment with systemic steroids or any other form of immunosuppressive therapy within 14 days prior to planned initiation of the Innocell vaccine; Note: Inhaled or topical steroids, including mouthwash, and adrenal replacement doses are permitted in the absence of active autoimmune disease.
  5. Congestive heart failure ( Class II, III, or IV), unstable angina, ventricular or hemodynamically significant atrial arrhythmia, or cardiovascular disease such as stroke or myocardial infarction (current or within the past 6 months).
  6. Has any acute infection that requires specific therapy. Acute therapy must be completed at least 7 days prior to initiation of Innocell series;
  7. Has received any live or attenuated vaccines against infectious diseases within 28 days of the planned vaccine initiation. Inactive vaccines, including SARS-CoV-2 vaccines authorized for use for active immunization to prevent COVID-19 are allowed and must be given in accordance with the prevailing immunization guidelines; or
  8. Has received any other agents within 4 weeks of planned vaccine initiation.
  9. Has received treatment with an approved systemic therapy within 4 weeks of planned vaccine initiation;
  10. Prior , except those that were treated curatively and have not recurred within 5 years prior to study treatment; resected basal cell and squamous cell skin cancers;
  11. History or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate, in the opinion of the treating investigator; or
  12. Inability of the subject to comply with study procedures and/or followup.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Dose Cohort -1

    Innocell 1.0 x 10\^6 cells + 3 mg CpG 1018 adjuvant administered ID every 2 weeks x 2 doses

    Biological: Innocell

  • Experimental
    Dose Cohort 1

    Innocell 1.0 x 10\^6 cells + 3 mg CpG 1018 adjuvant administered ID every 2 weeks x 3 doses

    Biological: Innocell

Interventions

  • BiologicalInnocell

    Innocell an autologous immunotherapy + CpG 1018 adjuvant

06

What researchers measure

Primary outcomes

  1. Success rate of autologous manufacturing

    Percent success rate to manufacture Innocell from autologous malignant tissue for patient administration

    Time frame: Approximately 2 months from Enrollment to Manufacturing release

  2. Safety assessed by treatment emergent adverse events

    Proportion of subjects experiencing treatment emergent adverse events

    Time frame: From enrollment until 30 days after the last dose of Innocell

Secondary outcomes

  1. Immune response to Innocell

    Mean change in circulating biomarkers (IgG1, IgG2, IgG3, IgA, IgM) via MILLIPLEX Human Isotyping Magnetic Bead Panel, or similar

    Time frame: Baseline to 60 days post last dose of Innocell

  2. Immune response to Innocell

    Mean change in circulating biomarkers (\~48 biomarkers - sCD40L, G-CSF, IFNα2;IFNγ;IL-1α;IL-1β;IL-1ra;IL-2;IL-3;IL-4, etc.) via MILLIPLEX Human Cytokine/Chemokine/Growth Factor Panel A (or similar)

    Time frame: Baseline to 60 days post last dose of Innocell

  3. Immune response to Innocell

    Mean change in circulating biomarkers including Complement C3a and Bb+ fragment ELISA

    Time frame: Baseline to 60 days post last dose of Innocell

  4. Immune response to Innocell

    Humoral Response to Innocell using ELISA assays

    Time frame: Baseline to 60 days post last dose of Innocell

  5. Evaluate disease burden

    CA-125 tumor marker

    Time frame: Baseline to 60 days post last dose of Innocell

  6. Immune response to Innocell

    Mean change in circulating cytokine levels

    Time frame: Baseline to 60 days post last dose of Innocell

  7. Immune response to Innocell

    Mean change in T-cell counts

    Time frame: Baseline to 30 days post last dose of Innocell

  8. Immune response to Innocell

    Determined by \> 1.5x over baseline via T-cell activation assay

    Time frame: Baseline to 30 days post last dose of Innocell

  9. Immunogenicity of Innocell Vaccine

    Correlation of % cancer cells in Innocell vaccine to immune response

    Time frame: Baseline to 60 days post last dose of Innocell

  10. Treatment Initiation

    Percentage of patients who receive the first dose of Innocell where the product was successfully manufactured and released

    Time frame: Approximately 2 months from Enrollment

  11. Clinical response

    Assessed by RECIST criteria v1.1 and iRECIST

    Time frame: Baseline to 60 days post last dose of Innocell, with long-term FU every 3 months x 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2028, 33 months after the start.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 33 months is below that.

Counting every sponsor, half of 382 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Nov 2026 → Nov 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 16, 2024
StartActual
Feb 12, 2026
Primary completionEst.
Nov 2028was Nov 2026
CompletionEst.
Dec 2028was Dec 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2026→Nov 2028
Nov 20, 2026
Study completion
Dec 2026→Dec 2028
Nov 20, 2026
Enrollment
8→12
Nov 20, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited, 2 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedHas histologically or cytologically confirmed diagnosis of advancedrecurrent epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy and for whom single-agent therapy is appropriate as the next line of treatment;
Exclusion criteria
  • EditedPositive clinical history ofPatient known to be positive for HIV, or patient with active HCV, HBV, HTLV-1/2;
  • RemovedActive or prior history of autoimmune disease;
  • AddedActive autoimmune disease that required systemic disease modifying or immunosuppressive treatment within the last 12 months. Replacement therapy (e.g., thyroxine or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is permitted;
  • AddedCongestive heart failure (NYHA Class II, III, or IV), unstable angina, ventricular or hemodynamically significant atrial arrhythmia, or cardiovascular disease such as stroke or myocardial infarction (current or within the past 6 months).
  • EditedHsHas received treatment with an approved systemic therapy within 34 weeks of planned vaccine initiation;
Nov 20, 2026
Interventions
Changed Innocell Autologous Cellular Immunotherapy→Innocell. Arms added: Dose Cohort -1·Dose Cohort 1; arms removed: Innocell an Autologous Cellular Immunotherapy
Nov 20, 2026
Primary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameSuccess rate of autologous manufacturing2 months → Approximately 2 months from Enrollment to Manufacturing release
  • Time frameSafety assessed by treatment emergent adverse eventsFrom 1st dose of Innocell until 30 days post last dose → From enrollment until 30 days after the last dose of Innocell
Nov 20, 2026
Secondary outcomes
6 time frame changed, 5 added, 5 description edited
What changed in the outcomes
  • AddedEvaluate disease burdenTime frame: Baseline to 60 days post last dose of Innocell
  • AddedImmune response to InnocellTime frame: Baseline to 60 days post last dose of Innocell
  • AddedImmune response to InnocellTime frame: Baseline to 30 days post last dose of Innocell
  • AddedImmune response to InnocellTime frame: Baseline to 30 days post last dose of Innocell
  • AddedTreatment InitiationTime frame: Approximately 2 months from Enrollment
  • Time frameImmune response to InnocellBaseline to 30 days post last dose of Innocell → Baseline to 60 days post last dose of Innocell
  • Time frameImmune response to Innocell#2Baseline to 30 days post last dose of Innocell → Baseline to 60 days post last dose of Innocell
  • Time frameImmune response to Innocell#3Baseline to 30 days post last dose of Innocell → Baseline to 60 days post last dose of Innocell
  • Time frameImmune response to Innocell#4Baseline to 30 days post last dose of Innocell → Baseline to 60 days post last dose of Innocell
  • Time frameImmunogenicity of Innocell VaccineBaseline to 30 days post last dose of Innocell → Baseline to 60 days post last dose of Innocell
  • Time frameClinical responseBaseline to 30 days post last dose of Innocell, with long-term FU every 3 months x 1 year → Baseline to 60 days post last dose of Innocell, with long-term FU every 3 months x 1 year
  • DescriptionClinical response: how it is measured was reworded
  • DescriptionImmune response to Innocell: how it is measured was reworded
  • DescriptionImmune response to Innocell#2: how it is measured was reworded
  • DescriptionImmune response to Innocell#3: how it is measured was reworded
  • DescriptionImmune response to Innocell#4: how it is measured was reworded
Nov 20, 2026
Contact
Study contact's phone or email changed: •••1040→•••7970. See the current contact
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Nov 2026→Nov 2028
    Study completion Dec 2026→Dec 2028
    Enrollment 8→12
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited, 2 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedHas histologically or cytologically confirmed diagnosis of advancedrecurrent epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy and for whom single-agent therapy is appropriate as the next line of treatment;
    Exclusion criteria
    • EditedPositive clinical history ofPatient known to be positive for HIV, or patient with active HCV, HBV, HTLV-1/2;
    • RemovedActive or prior history of autoimmune disease;
    • AddedActive autoimmune disease that required systemic disease modifying or immunosuppressive treatment within the last 12 months. Replacement therapy (e.g., thyroxine or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is permitted;
    • AddedCongestive heart failure (NYHA Class II, III, or IV), unstable angina, ventricular or hemodynamically significant atrial arrhythmia, or cardiovascular disease such as stroke or myocardial infarction (current or within the past 6 months).
    • EditedHsHas received treatment with an approved systemic therapy within 34 weeks of planned vaccine initiation;
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameSuccess rate of autologous manufacturing2 months → Approximately 2 months from Enrollment to Manufacturing release
    • Time frameSafety assessed by treatment emergent adverse eventsFrom 1st dose of Innocell until 30 days post last dose → From enrollment until 30 days after the last dose of Innocell
    Secondary outcomes 6 time frame changed, 5 added, 5 description edited
    What changed in the outcomes
    • AddedEvaluate disease burdenTime frame: Baseline to 60 days post last dose of Innocell
    • AddedImmune response to InnocellTime frame: Baseline to 60 days post last dose of Innocell
    • AddedImmune response to InnocellTime frame: Baseline to 30 days post last dose of Innocell
    • AddedImmune response to InnocellTime frame: Baseline to 30 days post last dose of Innocell
    • AddedTreatment InitiationTime frame: Approximately 2 months from Enrollment
    • Time frameImmune response to InnocellBaseline to 30 days post last dose of Innocell → Baseline to 60 days post last dose of Innocell
    • Time frameImmune response to Innocell#2Baseline to 30 days post last dose of Innocell → Baseline to 60 days post last dose of Innocell
    • Time frameImmune response to Innocell#3Baseline to 30 days post last dose of Innocell → Baseline to 60 days post last dose of Innocell
    • Time frameImmune response to Innocell#4Baseline to 30 days post last dose of Innocell → Baseline to 60 days post last dose of Innocell
    • Time frameImmunogenicity of Innocell VaccineBaseline to 30 days post last dose of Innocell → Baseline to 60 days post last dose of Innocell
    • Time frameClinical responseBaseline to 30 days post last dose of Innocell, with long-term FU every 3 months x 1 year → Baseline to 60 days post last dose of Innocell, with long-term FU every 3 months x 1 year
    • DescriptionClinical response: how it is measured was reworded
    • DescriptionImmune response to Innocell: how it is measured was reworded
    • DescriptionImmune response to Innocell#2: how it is measured was reworded
    • DescriptionImmune response to Innocell#3: how it is measured was reworded
    • DescriptionImmune response to Innocell#4: how it is measured was reworded
    Interventions Changed Innocell Autologous Cellular Immunotherapy→Innocell. Arms added: Dose Cohort -1·Dose Cohort 1; arms removed: Innocell an Autologous Cellular Immunotherapy
    Contact Study contact's phone or email changed: •••1040→•••7970. See the current contact
    + 4 other changes: verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06366490
Lead sponsor
PhotonPharma, Inc.
Responsible party
Sponsor
First posted
Apr 16, 2024
Start date
Feb 12, 2026
Primary completion
Nov 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Beth Crump, RN, BSN
Contact
beth.crump@photonpharma.net
303-981-1120
Thomas Bogenrieder, MD, Ph.D.
Contact
thomas.bogenrieder@photonpharma.net
+43 676 620 7970

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion